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Survival, by Birth Weight and Gestational Age, in Individuals With
Congenital Heart Disease: A Population-Based Study
Kate E. Best, PhD; Peter W.G. Tennant, PhD; Judith Rankin, PhD
Background-—Congenital heart disease (CHD) survival estimates are important to understand prognosis and evaluate health and
social care needs. Few studies have reported CHD survival estimates according to maternal and fetal characteristics. This study
aimed to identify predictors of CHD survival and report conditional survival estimates.
Methods and Results-—Cases of CHD (n=5070) born during 1985–2003 and notiﬁed to the Northern Congenital Abnormality
Survey (NorCAS) were matched to national mortality information in 2008. Royston–Parmar regression was performed to
identify predictors of survival. Five-year survival estimates conditional on gestational age at delivery, birth weight, and year of
birth were produced for isolated CHD (ie, CHD without extracardiac anomalies). Year of birth, gestational age, birth weight,
and extracardiac anomalies were independently associated with mortality (all P≤0.001). Five-year survival for children born at
term (37–41 weeks) in 2003 with average birth weight (within 1 SD of the mean) was 96.3% (95% CI, 95.6–97.0). Survival
was most optimistic for high-birth-weight children (>1 SD from the mean) born post-term (≥42 weeks; 97.9%; 95% CI,
96.8–99.1%) and least optimistic for very preterm (<32 weeks) low-birth-weight (<1 SD from mean) children (78.8%; 95% CI,
72.8–99.1).
Conclusions-—Five-year CHD survival is highly inﬂuenced by gestational age and birth weight. For prenatal counseling, conditional
survival estimates provide best- and worst-case scenarios, depending on ﬁnal gestational age and birth weight. For postnatal
diagnoses, they can provide parents with more-accurate predictions based on their baby’s birth weight and gestational age. ( J Am
Heart Assoc. 2017;6:e005213. DOI: 10.1161/JAHA.116.005213.)
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C ongenital heart disease (CHD) is a range of structuralanomalies of the heart, which affect around 1% of
births.1 Individuals with CHD often require complex life-saving
surgeries in infancy and lifetime follow-up.2 Survival estimates
are therefore important to understand prognosis and evaluate
health and social care needs. Our recent systematic review of
16 population-based studies estimated a 5-year survival of
85%, ranging from 14% for hypoplastic left heart to 96% for
ventricular septal defect.3 CHD survival is strongly inﬂuenced
by gestational age at birth, birth weight, and the presence of
extracardiac anomalies (ie, additional congenital anomalies
outside the cardiovascular system),4–9 but there is conﬂicting
evidence for plurality, maternal age, ethnicity, and socioeco-
nomic deprivation.4–11 Previous studies of CHD mortality tend
to report hazard ratios (HRs) without reporting survival
estimates, which have greater utility for counseling and
service planning.
The aim of this study is to estimate long-term survival of
individuals with CHD, born in the North of England during
1985–2003, conditioned on important determinants.
Methods
Case Inclusion
The Northern Congenital Abnormality Survey (NorCAS) is a
population-based register that collects data on cases of
congenital anomalies delivered to women residing in the
North of England (Figure). Cases diagnosed up to age
16 years (age 12 years after 2001) are notiﬁed from multiple
sources, including prenatal ultrasound, fetal medicine, cyto-
genetic laboratories, the regional cardiology center, pathology
and paediatric surgery, and coded using the World Health
Organization International Classiﬁcation of Diseases.
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Cases with CHD (International Classiﬁcation of Diseases,
Tenth Revision: Q20–26) live born between January 1, 1985
and December 31, 2003 were included. Cases with a single
minor CHD, for example, patent ductus arteriosus born
<37 weeks’ gestation, were excluded as per European
Surveillance of Congenital Anomalies guidelines.12
Survival Status
Deaths before age 1 year were identiﬁed from the region’s
Perinatal Mortality Survey, which is linked to the NorCAS
through the mother’s details. The Perinatal Mortality Survey
collects data on infant deaths from statutory death registra-
tions for infants whose mothers reside in the North of England
(Figure). Deaths beyond age 1 year were identiﬁed by linking
with national death registrations from the Ofﬁce for National
Statistics. The linkage was performed on January 28, 2008
using “fuzzy matching” by infant name, last known address,
mother’s age at delivery and sex. Cases not on the Perinatal
Mortality Survey or matched with Ofﬁce for National Statistics
records (eg, birth certiﬁcates) were cross-referenced with the
NorCAS or hospital records and located through the National
Health Service National Strategic Tracing Service. Those that
could not be traced were excluded (0.5%). Cases with
matched death registrations were classiﬁed as deceased on
their date of death; those without were coded as alive and
censored on the date the linkage was performed.
Ethical Approval
The NorCAS has approval from the Conﬁdentiality Advisory
Group of the Health Research Authority (PIAG 2-08(e)/2002)
to hold data without consent and, at the time of study, ethics
approval (09/H0405/48) to undertake research involving the
data. This study was given a favorable ethical opinion by the
South Tees Local Research Ethics Committee.
Data
Using a fetal growth formula, birth weight at 40 weeks
gestational age was predicted for all cases (based on their
actual birth weight and gestational age).13 Regional birth
weight references were applied to this formula, with
standardization for gestational age at birth, sex, and
plurality.13,14
From mothers’ residential postcode at delivery, the Index
of Multiple Deprivation 2004 was calculated. Index of Multiple
Deprivation is a measure of area-level socioeconomic depri-
vation calculated from income, employment, health, educa-
tion, access to services, social environment, housing stress,
living environment, and crime.15,16 Index of Multiple Depriva-
tion rank, which ranges from 1 for the most deprived area to
32 844 for the least deprived area, was categorized as least,
average, and most deprived tertiles. The tertiles were created
regionally to allow almost equal numbers of cases to be
assigned to each category.
Figure. Map showing the area covered by the Northern Congenital Abnormality Survey.
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The following were investigated as risk factors of mortality:
year of birth (continuous); maternal age at birth (continuous);
extracardiac anomalies (none, structural, or chromosomal/
genetic); standardized birth weight (low [z <1], average
[1≤ z ≤1], high [z >1]); gestational age at birth (very preterm
[<32 weeks]; moderate preterm [32–36 weeks]; term
[37–41 weeks]; post-term [≥42 weeks]); socioeconomic
deprivation (least, average, or most deprived), infant sex
(male or female); and plurality (singleton or twin). CHD
severity was coded into 4 groups (I [most severe], II, III [least
severe], and “unclassiﬁed”), using a slightly adapted version of
Khoshnood et al’s coding system.17 Unclassiﬁed CHD
includes patent ductus (≥37 weeks), congenital heart block,
dextrocardia, and aortic regurgitation, among others. Cases
with multiple subtypes were coded according to the most
severe and thus may vary from those previously reported from
these data.18 Table 1 shows which CHD subtypes are in each
severity category.
Statistical Analysis
Unadjusted and adjusted HRs were estimated using propor-
tional hazards Royston–Parmar models, with 1 knot. Para-
metric models such as Royston–Parmar models differ from
the traditionally used semiparametric Cox model because
they directly model the baseline hazard.19 This results in
smoother and therefore more-precise predictions of survival
than those resulting from the Cox model. The Royston–
Parmar approach in particular makes no speciﬁc distribu-
tional assumptions (as is the case for other parametric
approaches such as the Weibull or exponential models),
instead modeling and smoothing the baseline hazard using
cubic splines to maximise model accuracy. Mean 5-year
survival estimates for composite CHD were estimated using
a Royston–Parmar model adjusted for birth weight, gesta-
tional age, extracardiac anomalies, and year of birth, and
reported for isolated CHD (ie, no extracardiac anomalies)
during the study’s most recent year of birth (ie, 2003).
Where there were 5 or more deaths per variable, mean
survival estimates were also estimated for individual CHD
subtypes. Here, Royston–Parmar models were ﬁtted with
dichotomization of gestational age (preterm [<37 weeks]
versus term [≥37 weeks]) and presence of extracardiac
anomalies (none versus any), attributed to low numbers.
Ninety-ﬁve percent CIs were estimated using the Delta
method.
The proportional hazards assumption was checked using
log-log plots and by comparing HRs for different categoriza-
tions of survival time. Martingale residuals were plotted
against continuous variables to check that the functional form
was linear. P<0.05 was considered statistically signiﬁcant and
analyses were performed in Stata software (version 14;
StataCorp LP, College Station, TX).
Results
Of 5093 cases of CHD, 5070 (99.5%) had known survival
status. Of these, 87.1% (95% CI, 86.2–88.0) survived to age
5 years, 86.7% (95% CI, 85.7–87.6%) to age 10 years and
85.2% (95% CI, 84.1–86.3) to age 20 years. Of cases with
isolated CHD, 91.2% (95% CI, 90.3–92.0) survived to age
5 years, 90.9% (95% CI, 90.0–91.8) to age 10 years, and
89.7% (95% CI, 88.5–90.7) to age 20 years.
Predictors of Survival
Year of birth (P<0.001), gestational age at birth (P<0.001),
birth weight (P<0.001), extracardiac anomalies (P<0.001),
CHD severity (P<0.001), maternal age (P=0.04), and
plurality of pregnancy (P=0.009) were all crudely associated
with survival (Table 1). For each year increase in year of
birth, the risk of mortality decreased by 7% (HR=0.93; 95%
CI, 0.92–0.94). Cases born very preterm and moderately
preterm were 4.33 (95% CI, 3.30–5.67; P<0.001) and 2.09
(95% CI, 1.74–2.52; P<0.001) times more likely to result in
mortality than term cases. Cases born post-term were 27%
less likely to result in mortality (HR=0.73; 95% CI, 0.43–
1.21), although this was not statistically signiﬁcant
(P=0.22). Compared with average birth-weight cases, low
birth weight cases were at increased risk of mortality
(HR=1.73; 95% CI, 1.48–2.03; P<0.001) and high birth
weight cases were at decreased risk of mortality, although
this did not reach statistical signiﬁcance in the univariable
model (HR=0.83; 95% CI, 0.65–1.06; P=0.13). For each year
increase in maternal age, the risk of mortality increased by
1% (HR=1.01; 95% CI, 1.00–1.02). The risk of mortality was
18% lower in cases resident in the region’s third least
deprived areas compared with the third most deprived (95%
CI, 0.68–0.98; P=0.04), although the total effect of
socioeconomic deprivation was not statistically signiﬁcant
(P=0.11). Cases from multiple pregnancies were 1.62 times
more likely to result in mortality than singletons (95% CI,
1.13–2.32). Cases with structural and chromosomal anoma-
lies were at quadrupled risks of mortality (HR=4.22; 95% CI,
3.38–5.27; P<0.001 and HR=4.11; 95% CI, 3.47–4.87;
P<0.001, respectively).
Year of birth (P<0.001), gestational age at birth
(P<0.001), birth weight (P=0.001), CHD severity (P<0.001),
and extracardiac anomalies (P<0.001) remained signiﬁcant
in the multivariable model, although the HRs were all
attenuated compared with univariable analyses (Table 1).
Plurality was no longer signiﬁcant (P=0.22), with the effect
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changing direction (adjusted HR=0.78; 95% CI, 0.53–1.15).
The small increased risk of mortality associated with
increasing maternal age was similar, but no longer statisti-
cally signiﬁcant (P=0.10).
Five-Year Conditional Survival Estimates
Most children with CHD were born at term with average birth
weight (53.7%, 54.7%, 52.1%, and 56.6%, respectively for
Table 1. Survival for All CHD According to Risk Factors
Risk Factors N (%) HR (95% CI) P Value aHR (95% CI) P Value
Year of birth (per y) 5070 (100) 0.93 (0.91–0.94) <0.001 0.94 (0.92–0.95) <0.001
Gestational age
Very preterm
(<32 weeks)
149 (2.9) 4.33 (3.3–5.67) <0.001 6.85 (5.11–9.18) <0.001
Moderately preterm
(32–36 weeks)
619 (12.2) 2.09 (1.74–2.53) 1.87 (1.54–2.27)
Term (37–41 weeks) 4040 (79.7) 1 (reference category) 1 (reference category)
Post-term (≥42 weeks) 172 (3.4) 0.73 (0.43–1.21) 0.65 (0.38–1.08)
Missing 90 (1.8)
Birth weight
Low (z <1) 1274 (59.0) 1.73 (1.48–2.03) <0.001 1.31 (1.11–1.55) 0.001
Average (1≤ z ≤1) 2935 (25.6) 1 (reference category) 1 (reference category)
High (z >1) 770 (15.5) 0.83 (0.65–1.06) 0.76 (0.59–0.98)
Missing 91
Extracardiac anomalies
None 4181 (82.5) 1 (reference category) <0.001 1 (reference category) <0.001
Structural 287 (5.7) 4.22 (3.38–5.27) 2.95 (2.34–3.72)
Chromosomal/genetic 602 (11.9) 4.11 (3.47–4.87) 3.07 (2.57–3.67)
Maternal age (per y) 4795 (94.6) 1.01 (1.00–1.02) 0.04 1.01 (1.00–1.02) 0.10
Missing 275 (5.4)
Sex
Male 2675 (52.8) 1 (reference category) 0.65 1 (reference category) 0.64
Female 2395 (47.2) 0.96 (0.83–1.12) 1.05 (0.9–1.22)
Deprivation
Most deprived 1690 (33.3) 1 (reference category) 0.11 1 (reference category) 0.20
Average deprived 1690 (33.3) 0.94 (0.78–1.12) 0.93 (0.78–1.11)
Least deprived 1689 (33.3) 0.82 (0.69–0.99) 0.84 (0.69–1.02)
Missing 1 (0.02)
Plurality
Singleton 4918 (97.0) 1 (reference category) 0.009 1 (reference category) 0.22
Multiple 151 (3.0) 1.61 (1.13–2.31) 0.78 (0.53–1.15)
Missing 1 (0.02)
Severity <0.001
I (most) 163 (3.2) 4.26 (3.45–5.25) 5.73 (4.61–7.13)
II 1579 (31.1) 1 (reference category) 1 (reference category)
III (least) 3032 (59.8) 0.15 (0.12–0.18) 0.19 (0.15–0.23)
Unclassified 296 (5.8) 0.55 (0.40–0.75) 0.49 (0.36–0.67)
aHR indicates adjusted hazard ratio; CHD, congenital heart disease; HR, hazard ratio.
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composite CHD, severity I, II, II, and unclassiﬁed CHD) and
only very few were both low birth weight and very preterm
(0.5%, 0.4%, 0.1%, 0.7%, and 0.1%, respectively, for any CHD,
severity I, II, III, and unclassiﬁed CHD).
Five-year survival for a child with isolated CHD, born at
term in 2003 with average birth weight, was estimated as
96.3% (95% CI, 95.6–97.0). This dropped to 83.1% (95% CI,
78.5–87.8) for very preterm births and 93.4% (95% CI, 91.9–
95.0) for moderately preterm births, but increased to 97.3%
(95% CI, 95.8–98.7) for post-term births. Five-year survival for
a child with isolated CHD, born at term in 2003 with low birth
weight, was estimated as 95.2% (95% CI, 94.2–96.3) and with
high birth weight was estimated as 97.2% (95% CI, 96.4–
98.0). Children with low birth weight born very preterm had
the worst prognosis (survival=78.8%; 95% CI, 72.8–84.7) and
children with high birth weight born post-term had the best
prognosis (survival=97.9%; 95% CI, 96.8–99.1; Table 2).
Five-year survival for a child with isolated CHD, born at
term in 2003 with average birth weight, was estimated as
58.8% (95% CI, 42.8–74.7) for a severity I CHD, 89.2% (95%
CI, 86.5–91.8) for severity II, 99.3% (95% CI, 99–99.6) for
severity III, and 98.1% (95% CI, 96.3–99.9) for unclassiﬁed.
Survival for selected CHD subtypes conditional on birth
weight and gestational age are shown in Table 2.
Discussion
Year of birth, gestational age at birth, birth weight, and
extracardiac anomalies were independently associated with
mortality in individuals with CHD. Most children (53.7%) with
isolated CHD were born at term with average birth weight. An
estimated 96.3% of isolated cases born at term in 2003, with
average birth weight, were alive at age 5 years. This ranged
from 58.8% for children with the most severe CHD subtypes
to 99.3% for the least severe. Five-year survival was most
optimistic (97.9%) for children born with high birth weight
post-term and was least optimistic (78.8%) for children born
very preterm with a low birth weight.
This study’s main strength is the use of data from a high-
quality, population-based register, which is notiﬁed from
multiple sources to maximize ascertainment. The NorCAS is
annually cross-validated with a pediatric cardiac database at
the local tertiary center. Complex cases are reviewed by
pediatric pathologists and clinical geneticists, and, where
relevant, diagnoses are conﬁrmed by postmortem. NorCAS
cases may be diagnosed at any age up to 16 years (12 after
2001), meaning that difﬁcult and late diagnoses are included.
However, cases born to mothers resident in the North of
England that move out of the UK before diagnosis may not be
picked up by the NorCAS. Given that the North of England is a
very stable population with little migration, this is likely to
apply to a very few cases.20 Only 23 cases (0.5%) were
untraced, virtually eliminating any potential bias from loss to
follow-up.
We uniquely present adjusted 5-year survival estimates,
overall, by CHD severity and by selected CHD subtypes.
Existing studies typically report survival for all CHD
combined, not accounting for modifying factors such as
extracardiac anomalies or preterm birth. We show that these
factors substantially inﬂuence survival (eg, 5-year survival for
common arterial trunk falls from 77.2% in term births with
average birth weight to 50.6% for preterm births with low
birth weight). Adjusted survival estimates are important for
health and social care planning. For prenatal counselling,
they can provide best- and worst-case scenarios, depending
on the ﬁnal gestational age and birth weight. For postnatal
diagnoses, they can provide parents with more-accurate
predictions based on their baby’s birth weight and gesta-
tional age.
Although one of the largest studies to examine the
inﬂuences of CHD survival, we still lacked power to assess
uncommon features (eg, high birth weight or post-term birth)
or factors with modest effect sizes (eg, socioeconomic
deprivation). Nonsigniﬁcant associations should therefore be
interpreted with care.
Simulation studies suggest that survival analysis requires a
minimum of 5 to 10 events per variable for adequate
statistical power.21–23 Our adjusted survival estimates for
individual subtypes and severity categories were derived from
models containing 4 dummy categorical variables and 1
continuous variable. To accurately report survival, we there-
fore required at least 20 deaths for each CHD subtype, which
meant several subtypes could not be examined individually.
Ethnicity and parity have previously been associated with
CHD mortality.6–9 Data notiﬁed to the NorCAS are collected
routinely in clinical settings, and these variables are poorly
recorded. Surgical and medical interventions are also not
recorded on the NorCAS, but likely impact survival. In
particular, for cases of hypoplastic left heart, survival may
be improved with palliative surgery, though many parents opt
for comfort care.24 Moreover, younger age at surgical
intervention appears to improve survival in children with
CHD.25–29 The NorCAS does not hold information on
morbidities such as sepsis or pulmonary hypertension, which
are more prevalent in children with CHD and increase the risk
of mortality.29–31
Without information on cause of death, we cannot conﬁrm
whether a cardiac event was the cause of death. Mortality
among cases with extracardiac anomalies may result from the
coincident anomaly, rather than the CHD. However, for severe
subtypes, the contribution of any additional anomalies is
diminished by the CHD lethality. To provide the most widely
relevant ﬁgures, we presented our adjusted survival estimates
for isolated CHD only.
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We found that CHD survival improved over time during
1985–2003. We therefore ﬁxed our survival estimates to the
latest year of study. Survival prospects are likely to have
improved since 2003, and this should be considered when
interpreting our estimates. Assuming trends increased at the
same rate until 2016, survival for cases born at term, with
average birth weight and isolated CHD, would have increased
form 96.3% to 98.7%. Similarly, survival for cases born very
preterm with low birth weight would have increased from
78.8% in 2003 to 91.9% in 2016. Survival for cases born post-
term with high birth weight would have increased from 97.9%
in 2003 to 99.3% in 2016.
Our Kaplan–Meier survival estimate of 87.8% at age
5 years is comparable to the pooled estimate of 85% reported
in our recent systematic review3 (after excluding Tennant
et al, which used overlapping data18).
In our study, cases with extracardiac anomalies experi-
enced 4-fold increased risk of mortality. Knowles et al and
Olsen et al similarly reported that children with extracardiac
anomalies were at increased risk of mortality, but with smaller
effect sizes.29,11 These discrepancies may result from Knowles
et al excluding cases with Down syndrome and Olsen et al
having a different case mix, with just half the proportion of
ventricular septal defects than our study (23% versus 43%).
We found that CHD survival improved over time, reﬂecting
the ﬁndings of several other population-based studies.5,8,11,32
This improvement is likely explained by many factors,
including the development of several surgical interventions.
For example, the Fontan operation and the Norwood surgery
were introduced in the UK in 1975 and 1993, respectively, to
enable palliative treatment for single ventricle, hypoplastic left
heart, and tricuspid atresia.33 Similarly, the arterial switch
operation was introduced to the UK in 1984, replacing the
atrial switch operations. Improving expertise as well as
general improvements in neonatal care (which enable survival
until surgical intervention) are likely to have contributed to the
ongoing improvements in survival. For example, prostaglandin
was introduced to the UK in 1978, helping patients to remain
stable before surgical intervention.34
We found that greater gestational age at birth was
associated with improved survival. Knowles et al also reported
an increased risk of mortality in preterm compared with term
cases (HR=1.43).29 The slightly smaller effect size may result
from Knowles et al examining only “serious CHD.” Fixler et al
similarly reported an increased risk of mortality in very preterm
cases (HR=2.80) and moderately preterm cases (HR=1.69), but
only included CHD subtypes with single-ventricle physiology.4
We found that increased standardized birth weight was
associated with improved survival. Wang et al and Oster et al
similarly reported that increased birth weight improved
survival.8,32 Cardiac operative mortality has been shown to
increase with lower birth weight and lower gestational age at
birth. Furthermore, among children with CHD, low gestational
age at birth poses an increased risk of necrotizing entercoli-
tis.35 Of course, in individuals without CHD, the risk of mortality
increases as gestational age and birth weight decreases.36,37
However, our increased risk of mortality associated with
moderately preterm birth in individuals with CHD (HR=2.09)
exceeds that reported by Crump et al in the general population
(HR=1.80 for babies born 28–33 weeks and HR=1.52 for
babies born 34–36 weeks versus 37–42 weeks).36
We found some evidence of an association between
maternal age at delivery and mortality. Wang et al and Oster
et al reported signiﬁcantly decreased mortality in cases born
to mothers respectively aged >35 years compared with 30 to
34 years (HR=0.88)8 and aged ≥30 years compared with
<30 years (HR=0.77),32 respectively. Other population-based
studies have reported no signiﬁcant association between CHD
survival and maternal age in cases with single-ventricle
physiology4,6 and atrioventricular septal defect, but showed
lower survival in children born to older mothers. Potentially the
association with maternal age is confounded by other factors,
such as CHD subtype, socioeconomic deprivation, and gesta-
tional age at birth, which all varied by maternal age in our data.
We found lower survival in cases from multiple pregnan-
cies. However, after accounting for other variables, this
association was no longer signiﬁcant. In our data, cases from
multiple births were 10 times more likely to be preterm, 1.5
times more likely to have low birth weight, and 2.5 times more
likely to have structural extracardiac anomalies. Therefore,
although twins on average have poorer prognoses, a term,
average-weight twin with isolated CHD should have the same
survival prospects as an equivalent singleton.
We found poorer survival of children with CHD born in the
most compared with the least deprived areas in the North of
England. Miller et al did not ﬁnd a signiﬁcant association
between socioeconomic position and atrioventricular septal
defect survival in the USA; however, survival decreased
linearly with decreasing level of deprivation.10 Area-based
deprivation is a complex and multifaceted exposure, with
many domains and correlates, only some of which may be
related to CHD survival. Detecting such an association may
require a larger data set with greater power or more detail on
the individual features of the exposure. While the impact may
be small for the individual, it may still be an important
determinant at the population level.
Conclusion
Twenty-year survival associated with CHD was 85.2%. Year of
birth, gestational age at birth, standardized birth weight, and
the presence of extracardiac anomalies were associated with
mortality in individuals with CHD. This information is impor-
tant for health and social care planning.
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